Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Feasibility of Inspiratory Muscle Training in People With Chronic Obstructive Pulmonary Disease (COPD) Who Decline Pulmonary Rehabilitation
The feasibility study will involve mixed methods, this means interviews as well as
assessment of treatment with inspiratory muscle training therapy (IMT). There are two
pathways within the study depending on whether people want to have inspiratory muscle
training. People who accept to have inspiratory muscle training will have assessments before
training, after 8 weeks of training and at 6 month follow up in addition to interviews
before and after the study (at 6 months). For those who choose not to have the inspiratory
muscle training the investigators will offer them an interview so that the investigators can
find out more about what might have made the study more appealing or what treatments they
would have preferred. The investigators will also ask if they wish to be followed up with
baseline assessments for the study period and if the investigators can access health
records.
Interviews
Semi-structured interviews lasting approximately an hour will be performed at the beginning
of the study with participants who accept the IMT pathway and those who decline IMT until no
knew themes are raised. These interviews will be used to provide information on reasons for
declining pulmonary rehabilitation, attitudes to exercise, attitudes to IMT, treatment
preferences and opinions regarding study design and outcome measures (see Interview Topic
guide). The interviews will be taped and transcribed verbatim. A follow up interview with
study participants who have received IMT will be conducted at 6 months addressing attitudes
to IMT and study design and whether they have decided that they wish to engage with other
services (such as pulmonary rehabilitation and smoking cessation).
Inspiratory Muscle Training (IMT) method
Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic
device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax).
This means that each breath in through the device is set at 60% of the maximum force you are
able to create when you breathe in rather than at full force. 30 breaths are performed at
high velocity (paced initially over a period of 15 minutes to allow recovery between each
breath through the device). Once established it is anticipated that each training session
should take no more than five minutes. Training is performed twice a day, 5 days per week
for the first 8 weeks. Training will be titrated (set to a level suitable for the
participant) and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks
training the participants are advised to continue training unsupervised, twice a day, 3
times per week for a further 18 weeks.
Status | Completed |
Enrollment | 10 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 35 Years and older |
Eligibility |
Inclusion Criteria: - People over the age of 35 - with stable COPD (having had no exacerbation needing antibiotics or steroids in the preceding four weeks) with breathlessness on Medical Research Council (MRC) scale of 3 or above who decline Pulmonary rehabilitation (MRC 3 is defined as "walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at own pace"). Exclusion Criteria: - History of spontaneous pneumothorax - incomplete recovery from a traumatic pneumothorax - asthma - known recently perforated eardrum - unstable angina - ventricular dysrhythmias - cerebral event or myocardial infarction within the last two months - not oral antibiotics or steroids for COPD exacerbation within the last four weeks |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United Kingdom | Community Services, Sheffield Teaching Hospitals | Sheffield | South Yorkshire |
Lead Sponsor | Collaborator |
---|---|
Sheffield Teaching Hospitals NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Health related quality of life (HRQOL) | HRQOL measured using the Chronic Respiratory Disease questionnaire (CRQ) and COPD Assessment Test. | Baseline, 8 weeks, 6 months | No |
Other | Anxiety and depression | Anxiety and depression measured using the Hospital Anxiety and Depression Questionnaire. | Baseline, 8 weeks, 6 months | No |
Other | Activity Monitory | Activity monitoring assessed using Sensewear Accelerometers (Sensewear Pro-Armband Bodymedia) worn for four days. | Baseline, 8 weeks, 6 months | No |
Other | Dyspnoea | Dyspnoea measured using the first 5 questions of the CRQ. Dyspnoea will also be measured by the modified BORG breathlessness score recorded pre and post IMT. | Baseline, 8 weeks, 6 months | No |
Other | Healthcare utilisation | Healthcare utilisation measured using patient diaries and electronic health records, and EQ5DL. | 6 months | No |
Primary | Recruitment | Recruitment of 10 participants for inspiratory muscle training and 10 participants for interview alone within a four month period. | 4 months | No |
Secondary | Adherence with Inspiratory muscle training | Adherence to IMT: measured using a customised electronic threshold device (Powerbreathe) recording data from baseline to 6 months. Adherence will also be assessed using participant diaries. | 6 months | No |
Secondary | Attrition rate. | Attrition rate over the 6 month course of treatment. | 6 months | No |
Secondary | Maximal inspiratory pressure (PiMax) | Inspiratory muscle strength: Maximal inspiratory pressure (PiMax) and Sniff Nasal pressure measured using the MicroRPM (Micromedical) at baseline, 8 weeks and 6 months. | Baseline, 8 weeks, 6 months | No |
Secondary | Acceptability | Acceptability of IMT, study design and outcome measures and engagement or intention to engage with other services will be addressed in interviews at baseline and at 6 months for participants. A single interview will be offered to those declining the IMT arm of the study. | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|